

Special Issue

Epigenetics in Congenital Diseases

Message from the Guest Editor

The increasing availability of genome sequencing has significantly contributed to the identification of the genetic causes of many congenital diseases. However, it is often observed that individuals with the same genetic mutation exhibit varying degrees of disease severity. Moreover, certain congenital diseases have been sequenced, but no causal gene has been found. Epigenetics is a rapidly growing field that explores how gene expression is regulated without changes to the protein-coding DNA. These can include modifications in DNA, histone, or RNA that can alter protein expression. Studies suggest that epigenetic changes may account for the variability observed in individuals with the same genetic mutation, and, in some cases, could be the underlying cause of certain diseases. This Special Issue will focus on recent advances related to epigenetics in congenital diseases. We invite submissions on a range of topics, including, but not limited to, epimutations, mutations in epigenetic regulators, mutations in gene regulatory regions, novel techniques for assaying epigenetics in diseases, and the development of epigenetic therapies for congenital diseases.

Guest Editor

Dr. Shifeng Xue

Department of Biological Sciences, National University of Singapore, 14 Science Dr 4, S1A #05-10, Singapore City 117543, Singapore

Deadline for manuscript submissions

closed (30 September 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/169779

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).